Sarepta says it won't pull Duchenne gene therapy, setting up showdown with FDA

Sarepta Therapeutics said it won't comply with an FDA request to stop shipping the company's treatment for Duchenne muscular dystrophy, following two patient deaths, likely setting up a high-profile battle with the agency over the ...